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Introduction: Thirty to 40% of patients with non-small cell lung
cancer (NSCLC) are older than 70 years and rarely are enrolled in
clinical trials. Moreover, in clinical practice,75% of patients older
than 65 years with metastatic NSCLC never receive any kind of
chemotherapy.
Purpose: To retrospectively evaluate the impact of age on efficacy
and toxicity of chemotherapy regimens in patients with advanced
NSCLC treated with the docetaxel-gemcitabine combination.
Patients and Methods: Pooled data from six clinical trials of the
Hellenic Oncology Research Group were analyzed. According to
their age, patients were divided into two groups: those with age70
years and those with 70 years.
Results: A total of 858 patients were included in this analysis. Six
hundred sixty-six (77.6%) patients were younger than 70 years,
whereas 192 (22.4%) patients where 70-year-old. Overall re-
sponse rate was 30.3% and 30.2% for patients 70 years and 70
years, respectively (p  0.974). The median time to tumor progres-
sion was 4.1 and 4.5 months for patients 70 years and 70 years,
respectively (p  0.948). Median overall survival was 9.9 and 9.2
months for patients 70 and 70, respectively (p  0.117). The
multivariate analysis revealed performance status (PS) (p  0.0001)
and stage (p  0.0001) as independent factors with significant
impact on the hazard of death. Chemotherapy was well tolerated, but
the incidence of grade III/IV mucositis was significantly higher in
elderly patients (0.2% versus 1.5% for patients 70 versus 70
years, respectively; p  0.011).
Conclusion: The docetaxel/gemcitabine regimen has a comparable
efficacy and tolerance in young (70 years) and elderly (70 years)
patients.
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Non-small cell lung cancer (NSCLC) accounts for 80% ofthe 170.000 new cases of lung carcinoma diagnosed
each year in the United States and remains the leading cause
of cancer-related death in Western countries.1 Surgery re-
mains the only curative treatment modality of patients with
NSCLC, but although one-third of them have resectable
disease upon diagnosis, less than 5% of the patients are
expected to be alive at 5 years.2,3
About 50% of newly diagnosed cases of NSCLC con-
cern patients older than 65 years, whereas 30 to 40% of cases
are diagnosed in patients older than 70 years.4 Data from the
Surveillance, Epidemiology, and End Results indicate that the
median time at diagnosis in NSCLC patients is 69 years.5
Furthermore, recent data suggest that during the last decade,
the incidence and mortality of NSCLC has decreased in
younger patients, whereas it has increased among older pa-
tients.6 On the basis of these observations, it becomes clear
that NSCLC represents a significant health problem in elderly
patients. However, elderly patients are frequently under-
represented in clinical trials evaluating new treatments in
NSCLC.7 Indeed, more than 75% of patients older than 65
years with metastatic NSCLC never receive any kind of
chemotherapy in the daily clinical practice.8
For over 10 years cisplatin-based chemotherapy repre-
sents the cornerstone treatment for advanced NSCLC. A large
meta-analysis of eight randomized trials including 778 pa-
tients of cisplatin-based chemotherapy compared with best
supportive care, demonstrated an advantage of chemotherapy
with a 27% reduction in risk of death, and an increase in
1-year survival rate of 10%.9 On the other hand, the toxicity
of cisplatin remains a serious clinical problem. Nausea and
emesis are often severe and delayed, and neurotoxicity, renal
toxicity and ototoxicity are significant and dose-related.
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Moreover, an important proportion of elderly NSCLC pa-
tients have significant concomitant cardiac or cardio-respira-
tory diseases and, thus, there may be a contraindication for
the administration of cisplatin. Several randomized phase III
trials have demonstrated that non-platinum doublets offer a
comparable benefit in terms of time to tumor progression
(TTP) and overall survival (OS) and therefore are considered
as an alternative therapeutic option, especially in elderly
patients with advanced/metastatic NSCLC.10–12
In elderly patients, clinical trials have clearly demon-
strated that single-agent chemotherapy offers a survival ben-
efit, compared with best supportive care.13 Regarding com-
bination therapy published results are conflicting and it is not
clear whether combination therapy offers benefit compared
with monotherapy or not.14,15 To evaluate the impact of age
on efficacy and toxicity of combination regimens we retro-
spectively reviewed data from six clinical trials10,11,16–18 of
patients with advanced NSCLC treated with the docetaxel-
gemcitabine combination as first line treatment. All patients’
data were derived from our clinical trials department database.
PATIENTS AND METHODS
Patients
This analysis pooled data from six clinical trials10,11,16–18
conducted by the Hellenic Oncology Research Group. Patients
participating in these trials had locally advanced or metastatic
(stage IIIB–IV) NSCLC and a World Health Organization PS of
0–2; all patients had received front-line treatment with the
docetaxel/gemcitabine (DG) regimen. All patients gave written
informed consent to participate in these studies and the trials
were approved by the Ethics and Scientific Committees of the
participating centers. All studies were conducted according to
the Helsinki Declaration and Good Clinical Practice guidelines.
Fifty-one chemotherapy-naive patients with NSCLC
treated with gemcitabine 900 mg/m2 on days 1 and 8 and
docetaxel 100 mg/m2 on day 8, every 3 weeks were included
in a phase II study, assessing the efficacy of the DG combi-
nation, as first line treatment in NSCLC.16
Another multicenter phase II study enrolled 121 pa-
tients with lung adenocarcinomas who received gemcitabine
1100 mg/m2 on days 1 and 8 plus docetaxel 100 mg/m2 on
day 8, every 3 weeks as first line therapy (unpublished data).
A multicenter randomized phase III trial compared the
efficacy of front-line cisplatin/docetaxel and DG combination
in patients with advanced NSCLC.10 Two hundred twenty-two
patients were treated with gemcitabine (1100 mg/m2, days 1 and
8) and docetaxel (100 mg/m2, day 8), every 3 weeks. No
significant differences were observed between the two arms
in terms of overall response rate (ORR), TTP, and OS.
Another multicenter, randomized phase III trial compared
the activity and tolerability of DG and vinorelbine/cisplatin
regimens in chemotherapy-naive NSCLC patients.11 One hun-
dred ninety-seven patients were assigned to the DG arm (gem-
citabine 1000 mg/m2, days 1 and 8; plus docetaxel 100 mg/m2,
day 8, every 3 weeks). Similarly, this trial also failed to dem-
onstrate any ORR, TTP, or OS difference between the two arms.
Furthermore, docetaxel monotherapy was compared
with DG doublet in the context of a randomized multicenter
phase III trial.17 One hundred eighty-six patients in the DG
arm received gemcitabine 1000 mg/m2 on days 1 and 8 plus
docetaxel 100 mg/m2 on day 8 every 3 weeks. A significantly
higher ORR (26.8% versus 11.6%, p  0.001) and OS (9.4
months versus 8.3 months, p  0.037) was observed in favor
of the doublet, while there was a trend towards a higher TTP
in patients receiving the combination regimen.
Finally, a randomized multicenter, phase III study com-
pared oral vinorelbine/gemcitabine combination with the DG
combination.18 Gemcitabine was administered at a dose of
1000 mg/m2 on days 1 and 8 and docetaxel at a dose of 75
mg/m2 on day 8. Although a significantly higher ORR was
observed with the DG combination (23% versus 11%, p 
0.018), there was no difference between the two arms in
terms of TTP and OS.
In all but one study, docetaxel was administered at the
dose of 100mg/m2 every 3 weeks and in all studies patients
received prophylactic G-CSF support to minimize the inci-
dence of severe and/or febrile neutropenia associated with the
high docetaxel dose. This attitude was decided to be followed
based on the results of our initial phase II study which was
one of the first to report the DG combination in NSCLC.16
Moreover, in all studies, the administered doses of gemcit-
abine were ranged from 900 to 1100 mg/m2. Therefore,
patients from all these trials were pooled together, because
inclusion criteria were similar, all chemotherapy regimens
were similarly administered on days 1 and 8 and, almost, with
similar doses, and furthermore, prophylactic administration
of G-CSF was stipulated by all trials.10,11,16–18
Statistical Analysis
According to their age, patients were divided into two
groups: those with age 70 years and those with 70 years.
Descriptive statistics for the patient group are reported as
mean, median, and range. Statistical comparisons between
group rates (proportions) were assessed by Pearson’s 2-
test.19 Differences between groups in terms of survival data
were assessed by the log rank and Wilcoxon test (Kaplan-
Meier analysis).20 OS was the primary end point of this
analysis. OS was measured from entry into the study until
death and the 1-year survival was estimated using the Kaplan-
Meier method; the time to disease progression was measured
from the enrollment to the study until the day of the first
evidence of disease progression. The duration of response
was calculated from the day of the first documentation of
response to disease progression.
RESULTS
Patients
A total of 858 patients were included in this analysis.
Six hundred sixty-six patients (77.6%) were younger than 70
years, whereas 192 (22.4%) patients where 70 years old.
Patients’ characteristics for the two age groups are presented
in Table 1. Most patients were men with stage IV NSCLC.
Treatment
The median number of administered cycles was 4 per
patient for both groups. The median dose density for docetaxel
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and gemcitabine was 29.0 mg/m2/wk and 616 mg/m2/wk,
respectively, for patients aged 70 years old. For elderly
patients, the median dose density was 29.9 mg/m2/wk and
613 mg/m2/wk for docetaxel and gemcitabine, respectively
(p  0.281 and p  0.899 for docetaxel and gemcitabine,
respectively). A dose reduction was done in 141 (21.2%)
patients aged 70 years old, whereas for patients aged 70
years, dose reduction was necessary for 46 (24%) (p 
0.410). Hematological toxicity was the reason for dose re-
duction in 39 (27.7%) patients aged 70 and 14 (30.4%)
patients aged 70-year-old; nonhematological toxicity was
the reason for dose reduction in 41 (29.1%) patients aged
70 years and 13 (28.3%) patients aged 70 years (p 
0.780). Toxicity was the reason for treatment discontinuation
in 39 (5.9%) patients aged 70 years and 14 (7.3%) patients
aged 70 years (p  0.467).
Response to Treatment
There was no difference in terms of complete response
rate between the two groups (1.4% for patients aged 70
years versus 1.6% for patients aged 70 years; p  0.740).
The activity of the DG regimen in the two age groups is
presented in Table 2. ORR was 30.3% and 30.2% for patients
aged70 years and 70 years, respectively (p  0.974).
Median response duration was 6.1 and 5.3 months for the
70 years and 70 years patients’ groups (p  0.060).
Time to Tumor Progression
The median TTP was 4.1 and 4.5 months for patients
aged 70 years and 70 years, respectively (p  0.948;
Table 3). Univariate analysis including age (70 years, 70
years), PS (0–1 versus 2), stage (IIIB versus IV), histology
(adenocarcinoma versus squamous), and sex (male versus
female), revealed that stage of the disease was the only factor
with a significant impact on TTP. Furthermore, a proportional
hazards (Cox) regression analysis also revealed that stage of
the disease had a significant effect on the hazard of relapse
(p  0.0001), while PS (2) has a marked but not significant
effect (p  0.067) (Table 4). The Kaplan-Meier curve for
TTP is presented in Figure 1.
Overall Survival
Median OS was 9.9 and 9.2 months for the group
younger than 70 years and 70 years, respectively (p 
0.117; Table 3 and Figure 2). The univariate and multivariate
TABLE 2. Response Rate According to Age Group
<70
(n  666)
>70
(n  192) p
CR 9 (1.4%) 3 (1.6%) 0.740
PR 193 (27.1%) 55 (28.6%) 0.732
Overall response
rate (CR  PR)
202 (30.3%) 58 (30.2%)
95% CI 24.53–32.55% 27.84–37.38% 0.974
SD 171 (25.7%) 56 (29.2%) 0.300
PD 293 (43.9%) 78 (40.6%)
CR, complete response; PR, partial response; CI, confidence interval; SD, stable
disease; PD, partial disease.
TABLE 3. Time to Tumor Progression and Overall Survival
According to Age Group
<70
(n  666)
>65
(n  192) p
TTP 0.948
Median (range) (mo) 4.1 (0.5–66.4) 4.5 (0.5–36.9)
95% CI 3.53–4.60 3.89–4.97
1-yr without progression 14.4% 17.6%
OS 0.117
Median (range) (mo) 9.9 (0.5–90.4) 9.2 (0.5–115.4)
95% CI 9.12–10.61 7.59–10.81
1-yr survival 40.7% 39.4%
2-yr survival 17.0% 10.4%
TTP, time to tumor progression; CI, confidence interval; OS, overall survival.
TABLE 1. Patients’ Characteristics According to Age
Age <70
(n  666)
Age >70
(n  192)
pNo % No %
Age, yr, median (range) 60 (34–69) 72 (70–78)
Sex 0.202
Male 577 86.6 173 90.1
Female 89 13.4 19 9.9
Stage 0.204
IIIB 197 29.6 66 34.4
IV 469 70.4 126 65.6
Histology 0.737
Squamous 313 47.0 96 50.0
Adeno ca 330 49.5 89 46.4
Unknown 23 3.5 7 3.6
PS 0.195
0  1 604 90.7 168 87.5
2 62 9.3 24 12.5
PS, performance status.
TABLE 4. Multivariate Analysis for TTP and OS
Hazard 95% CI p
TTP
Age, 70 yr vs 70 yr 1.001 0.846–1.184 0.991
PS, 2 vs 0–1 1.240 0.985–1.560 0.067
Stage, IV vs IIIB 1.314 1.128–1.530 0.0001
Histology 1.060 0.921–1.220 0.416
Adeno ca vs squamous
Sex, female vs male 1.030 0.833–1.274 0.782
OS
Age, 70 yr vs 70 yr 1.140 0.952–1.365 0.155
PS, 2 vs 0–1 1.579 1.248–1.997 0.0001
Stage, IV vs IIIB 1.653 1.397–1956 0.0001
Histology, adeno Ca vs squamous 1.086 0.935–1.261 0.281
Sex, female vs male 1.108 0.889–1.382 0.362
TTP, time to tumor progression; PS, performance status; OS, overall survival.
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analysis revealed that stage of the disease (p  0.0001) and
performance status (p  0.0001) were independents factor
with significant impact on the hazard of death (Table 5).
Safety
The most frequent grade III/IV toxicity observed with
the DG regimen was neutropenia, which occurred in 197
(22.9%) patients. However, there was no difference regarding
the incidence of neutropenia between the two age groups
(p  0.808). On the contrary, the incidence of grade III/IV
mucositis was significantly higher for elderly patients (0.2%
versus 1.5% for patients70 versus70 years, respectively;
p  0.011). Similarly, there was a trend towards a higher
incidence of diarrhea in elderly patients (2.1% versus 4.6%
for patients aged 70 years versus 70 years, respectively;
p  0.051). No other significant difference was observed
(Table 5).
DISCUSSION
Lung cancer at the elderly population is a significant
public health problem. At present, about 66% of newly
diagnosed NSCLC patients are older than 65 years and about
one third is older than 75 years.21 Despite this fact, until
recently elderly patients were under-presented in clinical
trials.7 Furthermore, several studies have demonstrated that
age is not a poor prognostic factor for OS in NSCLC.22–24 The
largest study, which included 5000 patients and evaluated the
prognostic impact of 77 variables in NSCLC, yielded that age
had no impact on survival, while the most important prog-
nostic factors for survival were PS, extent of disease and
weight loss in the last 6 months.24
Our data are in agreement with the above observations.
The retrospective analysis of individual patients’ data partic-
ipating in six clinical trials,10,11,16–18 yielded no significant
difference in terms of response rate, TTP and OS between
patients aged 70 years old, when compared with patients
aged 70 years old; elderly patients seem to benefit from the
DG regimen in a similar way like younger patients do.
However, given the retrospective nature of this study, these
results should be interpreted with caution.
The toxicity profile of DG regimen was also favorable
in elderly patients. Indeed there was no significant difference
in terms of toxicity between younger and older patients, with
the exception of mucositis (p  0.011) and diarrhea (p 
FIGURE 1. Kaplan-Meier curve for TTP, for patients 70
years and 70 years old. TTP, time to tumor progression.
FIGURE 2. Kaplan-Meier survival curve for patients 70
years and 70 years old.
TABLE 5. Toxicity According to Age Group
<70
(n  666)
<70
(n  192)
<70
(n  666)
<70
(n  192)
<70
(n  666)
<70
(n  192)
<70
(n  666)
<70
(n  192)
pa
I I II II III III IV IV
N N N N N N N N
Neutropenia 75 (11.5) 21 (21.9) 60 (9.0) 20 (10.4) 97 (14.6) 14 (7.3) 59 (8.9) 27 (14.1) 0.808
Febrile neutropenia 6 (0.9) 2 (1.0) 7 (1.1) 1 (0.5) 11 (1.7) 1 (0.5) 243.6 7 (3.6) 0.542
Thrombo/penia 207 (31.1) 53 (27.6) 36 (5.4) 14 (7.3) 12 (1.8) 7 (3.6) 111.7 4 (2.1) 0.154
Anemia 375 (56.3) 102 (53.1) 179 (26.9) 60 (31.3) 23 (3.5) 5 (2.6) 4 (0.6) — 0.350
Nausea/vomiting 89 (13.4) 28 (14.6) 44 (6.6) 11 (5.7) 6 (0.9) 1 (0.5) — 2 (1.0) 0.428
Diarrhea 55 (8.3) 16 (8.3) 46 (6.9) 11 (5.7) 12 (1.8) 7 (3.6) 2 (0.3) 2 (1.0) 0.051
Mucocitis 22 (3.3) 4 (2.1) 11 (1.1) 4 (2.1) — 2 (1.0) 1 (0.2) 1 (0.5) 0.011
Neurotoxicity 60 (9.0) 14 (7.3) 28 (4.2) 7 (3.6) 9 (1.4) 3 (1.6) 2 (0.3) 1 (0.5) 0.688
Fatigue 192 (28.8) 44 (22.9) 117 (17.6) 37 (19.3) 21 (3.2) 11 (5.7) 3 (0.5) — 0.190
a Grade III/IV.
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0.051). The higher incidence of mucositis and diarrhea in
elderly is an expected observation; changes with age within
the gastrointestinal system can result in decreased gastroin-
testinal motility, reduced blood flow and secretion of diges-
tive enzymes, and mucosal atrophy, and this is a possible
explanation for the higher incidence of mucositis.25
The optimal treatment for elderly patients with ad-
vanced NSCLC remains to be determined. A phase III mul-
ticenter trial in 191 patients (the Elderly Lung Cancer Vi-
norelbine Italian Study) showed that single-agent vinorelbine
improved quality of life and survival compared with support-
ive care alone (median survival, 27 versus 21 weeks, respec-
tively; p  0.04).13 Furthermore, a recently published ran-
domized phase III trial, compared docetaxel (60 mg/m2 day 1
every 3 weeks) with vinorelbine (25 mg/m2 i.v on days 1 and
8, every 3 weeks), as first line treatment, in elderly patients
with advanced NSCLC.26 The trial enrolled 182 patients and
provided significantly longer progression-free survival (5.5
months versus 3.1 month; p  0.001) and ORR (22.7%
versus 9.9%; p  0.019) as well as a better, although not
statistically significant, 1-year survival rate (58.6% versus
36.7%) in favor of docetaxel; the OS was numerically but not
statistically significantly higher for the docetaxel arm when
compared with the vinorelbine arm (14.3 months versus 9.9
months, respectively).
To improve the results obtained with single-agent che-
motherapy in elderly patients, non-platinum-based combina-
tions have been developed. The combination of gemcitabine/
vinorelbine is the most studied regimen but the results are
conflicting. Frasci et al.14 compared the combination of vi-
norelbine/gemcitabine with vinorelbine alone. An interim
analysis conducted on the first 120 patients demonstrated a
significant benefit in favor of the combination arm, resulting
in a premature trial discontinuation. Median survival time
was 7 months for the combination arm and only 4.5 months
for single-agent vinorelbine. This study was seriously criti-
cized, because, single-agent vinorelbine arm outcome was
similar to the outcome frequently described with supportive
care alone. The subsequent Multicenter Italian Lung Cancer
in the Elderly Study phase III trial compared the vinorelbine/
gemcitabine combination with single-agent gemcitabine or
vinorelbine.15 This trial failed to demonstrate any benefit in
favor of combination chemotherapy. For vinorelbine, gem-
citabine, and the combination, median survival was 36, 28,
and 30 weeks, respectively, and the probabilities of being
alive at 1 year were 38%, 28%, and 30%, respectively.15
Although, cisplatin-based doublets are considered as
the standard treatment in advanced NSCLC,27 no prospec-
tive randomized phase III data support this fact in elderly
population. However, retrospective data from many inves-
tigators support that elderly patients experienced more
profound myelotoxicity and had greater risk of chemother-
apy-related death from cisplatin administration than
younger patients.28,29
Evaluating the different treatment options for elderly
patients with NSCLC, it is very important to effectively select
these patients who are suitable for chemotherapy. A compre-
hensive geriatric assessment should always be done, with the
use of validated instruments. This will allow the clinical
oncologist to evaluate functional status, comorbidities, socio-
economic status, nutritional status, polypharmacy, and the
presence of geriatric syndromes.30 This approach will allow
the identification of potentially treatable problems (such as
depression or malnutrition) that may otherwise decrease tol-
erability and increase toxicity and consequently to compro-
mise the outcome. In summary, this retrospective analysis of
pooled data clearly demonstrates that the combination of
docetaxel and gemcitabine is an active and well-tolerated
regimen for elderly patients with advanced/metastatic NSCLC.
Although in a previous study we demonstrated that the DG
regimen is superior to docetaxel monotherapy in the general
population17 this remains to be specifically proved in elderly
patients in the context of a prospective randomized trial.
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